Itepekimab is a human immunoglobulin G (IgG)4P monoclonal antibody targeting interleukin-33 (IL-33), currently under development for treating chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and bronchial asthma. It has been shown to significantly reduce the incidence of moderate-to-severe acute exacerbations in COPD, lower the rate of uncontrolled asthma, improve lung function, and enhance quality of life. The drug demonstrates a favorable safety and tolerability profile, with common adverse events including headache, nasopharyngitis, gastrointestinal reactions, back pain, and others. This paper provides an overview of the mechanism of action, pharmacokinetics, pharmacodynamics, animal studies, clinical research, and safety profile of Itepekimab.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |